arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Vericel Corporation

VCEL Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$42.97
▲ +5.9% Today
as of Oct 22, 16:53 ET
Last 30 days +8.51% Sep 14 → Oct 22
$38.46 $39.67 $40.88 $42.09 $43.30 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$41.21
High
$43.01
Low
$40.02
Volume
$604,931
Avg Vol
$585,577
Mkt Cap
$2.1B
P/E (TTM)
—
Beta
—
52w High
$49.32
52w Low
$28.95
Div Yield
—
Shares Out
$51M

Recent Press Releases & News last 60 days · 4 items

Oct 22 · 12:30 PR GlobeNewswire
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
Oct 14 · 12:23 MT Newswires
Truist Securities Adjusts Vericel Price Target to $52 From $58, Maintains Buy Rating
Sep 26 · 22:06 Simply Wall St.
Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
▸ Show all 4 press releases & news Free account →

VCEL earnings at a glance

Vericel Corporation (VCEL) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of $0.02, compared with $0.10 in the same quarter last year (-80%). The options market is pricing a move of about ±12.6% after the report, a range of roughly $37.55 to $48.39 from today's $42.97. Over its last 6 reports the stock rose the next day 4 times and fell 2, moving ±5.0% on average; after the most recent report on Jul 30, 2026 it moved +2.1%. That means options currently expect more movement than VCEL has typically delivered. VCEL beat the consensus EPS estimate in 4 of its last 6 reported quarters. Implied volatility is currently 107%. The share price of $42.97 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$29
$49
69% of range
Avg surprise (last 6)
+123.2%
Avg reaction (last 6)
-1.2%
67% positive
Latest IV / EM
107%
EM ±12.6% · $40 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.23$-0.06$0.11$0.28$0.45 Actual $-0.16Actual $-0.11Actual $-0.08Actual $-0.08Actual $-0.10Actual $-0.02Actual $-0.23Est $-0.09Actual $-0.01Est $-0.04Actual $0.10Est $-0.02Actual $0.45Est $0.45Actual $-0.12Est $-0.15Actual $0.04Est $-0.04 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-11M$12M$35M$58M$81M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 30, 2026Jun/2026 $0.04 $-0.04 +200.0% -300.0% +2.1% earnings
Thu May 7, 2026Mar/2026 $-0.12 $-0.15 +20.0% +47.8% -4.5% earnings
Thu Feb 26, 20268K 2026-02-26 $0.45 $0.45 0.0% — +1.6% earnings
Thu Nov 6, 2025Sep/2025 $0.10 $-0.02 +600.0% — +4.2% earnings
Thu Jul 31, 2025Jun/2025 $-0.01 $-0.04 +75.0% — -14.1% earnings
Thu May 8, 2025Mar/2025 $-0.23 $-0.09 -155.6% — +3.5% earnings
Mon Sep 30, 2024Sep 2024 $-0.02 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.10 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.08 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.08 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.11 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.16 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER $0.02$0.10 -80.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$77M$68M—$68M$63M$53M—$58M
Cost of revenue$21M$19M—$18M$17M$16M—$16M
Gross profit$56M$49M—$50M$47M$36M—$42M
Operating income$434,000$-8M—$3M$-2M$-13M—$-2M
Net income$2M$-6M—$5M$-553,000$-11M—$-901,000
EPS (diluted)$0.04$-0.12—$0.10$-0.01$-0.23—$-0.02

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$125M$109M$100M$100M$81M$73M$75M$54M
Inventory$18M$18M$18M$18M$17M$17M$17M$16M
Total current assets$265M$244M$247M$222M$205M$198M$213M$191M
Total assets$503M$486M$488M$453M$436M$425M$433M$390M
Long-term debt————————
Total liabilities$133M$129M$133M$131M$129M$129M$141M$133M
Total equity$370M$356M$355M$322M$307M$295M$292M$257M

Implied volatility — last 90 days

42%109%177%244%312% Jun 08 — IV 123% · EM ±16.2%Jun 09 — IV 119% · EM ±14.9%Jun 10 — IV 127% · EM ±15.0%Jun 11 — IV 120% · EM ±13.2%Jun 12 — IV 172% · EM ±17.6%Jun 15 — IV 112% · EM ±8.1%Jun 16 — IV 136% · EM ±8.1%Jun 17 — IV 312% · EM ±13.0%Jun 19 — IV 52% · EM ±11.5%Jun 22 — IV 57% · EM ±12.0%Jun 23 — IV 57% · EM ±11.8%Jun 24 — IV 95% · EM ±19.0%Jun 25 — IV 84% · EM ±16.6%Jun 26 — IV 60% · EM ±11.5%Jun 29 — IV 43% · EM ±7.5%Jun 30 — IV 69% · EM ±11.9%Jul 01 — IV 68% · EM ±11.3%Jul 02 — IV 69% · EM ±11.2%Jul 03 — IV 72% · EM ±11.3%Jul 06 — IV 80% · EM ±11.1%Jul 07 — IV 82% · EM ±10.9%Jul 08 — IV 92% · EM ±11.5%Jul 09 — IV 58% · EM ±6.9%Jul 10 — IV 98% · EM ±10.9%Jul 13 — IV 137% · EM ±11.5%Jul 14 — IV 153% · EM ±11.1%Jul 15 — IV 188% · EM ±11.1%Jul 16 — IV 255% · EM ±10.7%Jul 20 — IV 63% · EM ±14.9%Jul 21 — IV 59% · EM ±13.7%Jul 22 — IV 59% · EM ±13.6%Jul 23 — IV 55% · EM ±12.4%Jul 24 — IV 61% · EM ±13.4%Jul 27 — IV 61% · EM ±12.8%Jul 28 — IV 65% · EM ±13.4%Jul 29 — IV 77% · EM ±15.4%Jul 30 — IV 68% · EM ±13.2%Jul 31 — IV 68% · EM ±13.1%Aug 03 — IV 69% · EM ±12.2%Aug 04 — IV 69% · EM ±11.8%Aug 05 — IV 67% · EM ±11.2%Aug 06 — IV 73% · EM ±11.8%Aug 07 — IV 72% · EM ±11.3%Aug 10 — IV 84% · EM ±11.6%Aug 11 — IV 87% · EM ±11.5%Aug 12 — IV 91% · EM ±11.4%Aug 13 — IV 95% · EM ±11.2%Aug 14 — IV 104% · EM ±11.5%Aug 17 — IV 140% · EM ±11.7%Aug 18 — IV 159% · EM ±11.5%Aug 19 — IV 197% · EM ±11.6%Aug 20 — IV 290% · EM ±12.1%Aug 24 — IV 70% · EM ±14.5%Aug 25 — IV 70% · EM ±14.3%Aug 26 — IV 86% · EM ±17.2%Aug 27 — IV 63% · EM ±12.4%Aug 28 — IV 65% · EM ±12.5%Aug 31 — IV 72% · EM ±12.8%Sep 01 — IV 73% · EM ±12.6%Sep 02 — IV 75% · EM ±12.5%Sep 03 — IV 78% · EM ±12.6%Sep 04 — IV 81% · EM ±12.7%Sep 07 — IV 92% · EM ±12.7%Sep 08 — IV 99% · EM ±13.1%Sep 10 — IV 123% · EM ±14.5%Sep 11 — IV 122% · EM ±13.4%Sep 14 — IV 154% · EM ±12.9%Sep 21 — IV 64% · EM ±13.4%Sep 22 — IV 66% · EM ±13.4%Sep 23 — IV 68% · EM ±13.7%Sep 24 — IV 69% · EM ±13.4%Sep 25 — IV 68% · EM ±13.0%Sep 28 — IV 74% · EM ±13.1%Sep 29 — IV 78% · EM ±13.4%Sep 30 — IV 75% · EM ±12.5%Oct 01 — IV 79% · EM ±12.7%Oct 02 — IV 72% · EM ±11.3%Oct 05 — IV 80% · EM ±11.1%Oct 06 — IV 95% · EM ±12.6%Oct 07 — IV 72% · EM ±9.1%Oct 08 — IV 107% · EM ±12.6%

Sector peers

BCRX
BioCryst Pharmaceuticals, Inc.
$2.1B $7.78-2.0%
ALVO
Alvotech
$2.2B $4.79-6.5%
VIR
Vir Biotechnology, Inc.
$1.9B $10.43-2.9%
ADMA
ADMA Biologics Inc
$2.3B $10.95-2.5%
RXRX
Recursion Pharmaceuticals, Inc.
$2.3B $3.58-2.2%
NVAX
Novavax, Inc.
$1.9B $9.99-12.6%

VCEL earnings FAQ

When is VCEL's next earnings date?

Vericel Corporation is expected to report on November 5, 2026.

What is VCEL's expected move for earnings?

Options currently price a move of about ±12.6%, or $5.42 per share either way from $42.97.

How does VCEL stock usually react to earnings?

Across the last 6 reports the average next-day move was ±5.0%, up 4 times and down 2 times.

What EPS are analysts expecting from Vericel Corporation?

The consensus estimate is $0.02 per share, versus $0.10 a year ago.

What is VCEL's implied volatility?

VCEL's at-the-money implied volatility is about 107% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in